Key result
Inpatient antithrombotic therapy linked to adverse drug reactions in ~17% of patients, mostly preventable.
Why the study?
Antithrombotic agents pose risks of adverse drug reactions, drug-drug interactions, and dosing challenges, and limited real-world data from the United Arab Emirates warranted evaluation of prescribing and monitoring practices.
What are the prescribing patterns, dosing deviations, and rates of adverse drug reactions and drug-drug interactions among adult inpatients receiving antithrombotic therapy in the United Arab Emirates?
Observational (n=100)
No
What are the prescribing patterns, dosing deviations, and rates of adverse drug reactions and drug-drug interactions among adult inpatients receiving antithrombotic therapy in the United Arab Emirates?
Real-world inpatient antithrombotic use in a UAE hospital showed frequent dosing deviations (overprescription of enoxaparin/aspirin, underdosing of apixaban), inconsistent coagulation monitoring, and notable rates of preventable adverse drug reactions (17%) and major drug-drug interactions.
Answers are grounded in this paper and cite their sources.
May warrant enhanced inpatient antithrombotic monitoring; leaves open whether dosing standardization reduces preventable events.
Introduction: Antithrombotic agents, including anticoagulants and antiplatelet drugs, are vital for preventing and managing thromboembolic events but pose risks of adverse drug reactions, drug-drug interactions, and dosing challenges. Limited real-world data from the United Arab Emirates warrant evaluation of prescribing and monitoring practices. This study aimed to assess prescribed daily doses of antithrombotic agents against World Health Organization-defined daily doses, evaluate related adverse drug reactions and drug-drug interactions, and analyze clinical outcomes. Methods: A prospective observational study was conducted over seven months at a private academic hospital in Ajman, United Arab Emirates. Adult inpatients receiving antithrombotic therapy were included. Data on demographics, medications, laboratory results, adverse drug reactions, and drug-drug interactions were collected. The World Health Organization Anatomical Therapeutic Chemical/Defined Daily Dose methodology was applied. Results: Of 130 patients screened, 100 were included. Antiplatelet drugs were prescribed to 67% and anticoagulants to 33%, with enoxaparin being the most frequent agent. Deviations from World Health Organization-defined daily doses were common, including overprescription of enoxaparin and aspirin and underdosing of apixaban. Adverse drug reactions occurred in 17% of patients, most commonly hematuria and thrombocytopenia; all were mild and 90% were preventable. Drug-drug interactions occurred in 10%, mainly pharmacodynamic, with 67% classified as major. Monitoring of coagulation parameters was inconsistent, with most patients not achieving therapeutic targets. Conclusion: The study revealed significant dosing variability, frequent adverse drug reactions and drug-drug interactions, and inadequate monitoring. Enhanced adherence to dosing guidelines and improved medication safety practices are essential to optimize outcomes in antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Menon et al. (2026) conducted an observational in Adult inpatients receiving antithrombotic therapy (n=100). Antithrombotic agents (antiplatelets and anticoagulants, including enoxaparin, aspirin, and apixaban) vs. World Health Organization-defined daily doses was evaluated on Adverse drug reactions, drug-drug interactions, and deviations from World Health Organization-defined daily doses. Antithrombotic therapy in hospitalized adults resulted in adverse drug reactions in 17% of patients (90% preventable) and drug-drug interactions in 10% (67% major).
Synapse has enriched 10 related papers. Consider them for comparative context: